Χώρα: Ηνωμένες Πολιτείες
Γλώσσα: Αγγλικά
Πηγή: NLM (National Library of Medicine)
DICLOFENAC SODIUM (UNII: QTG126297Q) (DICLOFENAC - UNII:144O8QL0L1)
Preferred Pharmaceuticals, Inc.
DICLOFENAC SODIUM
DICLOFENAC SODIUM 50 mg
ORAL
PRESCRIPTION DRUG
Carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS: Gastrointestinal Bleeding, Ulceration and Perforation ). Diclofenac sodium delayed-release tablets are indicated: Diclofenac sodium delayed-release tablets are contraindicated in the following patients.
HOW SUPPLIED 50 mg: round, light brown, enteric-coated tablets P 50 imprinted on one side in black ink and plain on the reverse side are supplied as: Bottle of 20 - 68788-9175-2 Bottle of 30 - 68788-9175-3 Bottle of 60 - 68788-9175-6 Bottle of 90 - 68788-9175-9 Bottle of 100 - 68788-9175-1 Bottle of 120 - 68788-9175-8 75 mg: round, light brown, enteric-coated tablets P 75 imprinted on one side in black ink and plain on the reverse side are supplied as: Bottle of 20 - 68788-9231-2 Bottle of 30 - 68788-9231-3 Bottle of 60 - 68788-9231-6 Bottle of 90 - 68788-9231-9 Bottle of 100 - 68788-9231-1 Bottle of 120 - 68788-9231-8 Store at 20° to 25°C (68° to 77°F) (see USP Controlled Room Temperature). Protect from moisture. Dispense in a tight, light-resistant container. Manufactured for: Rising® Rising Pharmaceuticals, Inc. Allendale, NJ 07401 1-800-521-5340 Manufactured by: UNIQUE PHARMACEUTICAL LABORATORIES (A Div. of J. B. Chemicals & Pharmaceuticals Ltd.) Mumbai 400 030, India. 121266 April 2017 Repackaged By: Preferred Pharmaceuticals Inc.
Abbreviated New Drug Application
DICLOFENAC SODIUM- DICLOFENAC SODIUM TABLET, DELAYED RELEASE PREFERRED PHARMACEUTICALS, INC. ---------- DICLOFENAC SODIUM DELAYED-RELEASE TABLETS, USP 25 MG, 50 MG AND 75 MG Rx only WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS CARDIOVASCULAR THROMBOTIC EVENTS • • GASTROINTESTINAL BLEEDING, ULCERATION, AND PERFORATION • DESCRIPTION Diclofenac sodium is a benzeneacetic acid derivative, designated chemically as 2-[(2,6- dichlorophenyl)amino] benzeneacetic acid, monosodium salt. The structural formula is: Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use (see WARNINGS). Diclofenac sodium delayed-release tablets are contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see CONTRAINDICATIONS and WARNINGS). NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events (see WARNINGS). C H CL NNAO M.W. 318.14 Diclofenac sodium is a white to off-white, hygroscopic crystalline powder. It is freely soluble in methanol, soluble in ethanol, sparingly soluble in water and practically insoluble in chloroform and in dilute acid. The n-octanol/water partition coefficient is 13.4 at pH 7.4 and 1545 at pH 5.2. Diclofenac sodium has a dissociation constant (pKa) of 4.0 ± 0.2 at 25°C in water. Each enteric-coated tablet for oral administration contains 25 mg, 50 mg, or 75 mg of diclofenac sodium. In addition, each tablet contains the following inactive ingredients. Inactive ingredients: lactose (monohydrate), microcrystalline cellulose, croscarmellose sodiu Διαβάστε το πλήρες έγγραφο